Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases

Drug Metabolism and Disposition

Volumn 38, Issue 3, 2010, Pages 386-395

  Manevski, Nenad ^a   Kurkela, Mika ^a   Höglund, Camilla ^a   Mauriala, Timo ^a   Court, Michael H ^b   Yli Kauhaluoma, Jari ^a   Finel, Moshe ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYINDOLE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; INDOLE ALKALOID; MESSENGER RNA; PSILOCIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HALLUCINOGENS; HUMANS; INDOLES; ISOENZYMES; KINETICS; LIVER; METABOLIC DETOXICATION, PHASE II; MICROSOMES; ORGAN SPECIFICITY; PSILOCYBINE; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBSTRATE SPECIFICITY; SULFHYDRYL REAGENTS;

EID: 76749091539     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.031138     Document Type: Article

References (35)

1. Anastos N, Barnett NW, Pfeffer FM, and Lewis SW (2006) Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography. Sci Justice 46:91-96.
2. Bjornstad K, Hulten P, Beck O, and Helander A (2009) Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials. Clin Toxicol (Phila) 47:566-572.
3. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433.
4. El-Bachá RS, Leclerc S, Netter P, Magdalou J, and Minn A (2000) Glucuronidation of apomorphine. Life Sci 67:1735-1745.
5. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566.
6. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, and Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53:439-452.
7. Grieshaber AF, Moore KA, and Levine B (2001) The detection of psilocin in human urine. J Forensic Sci 46:627-630.
8. Halpern JH (2004) Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 102:131-138.
9. Hasler F, Bourquin D, Brenneisen R, and Vollenweider FX (2002) Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. J Pharm Biomed Anal 30:331-339.
10. Hasler F, Bourquin D, Brenneisen R, Bär T, and Vollenweider FX (1997) Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv 72:175-184.
11. Holzmann PP (1995) Bestimmung van Psilocybin-Metaboliten im Human Plasma and Urin. Ph.D. thesis, Eberhard-Karls-Universitat, Tubingen, Germany.
12. Ikushiro S, Emi Y, and Iyanagi T (2002) Activation of glucuronidation through reduction of a disulfide bond in rat UDP-glucuronosyltransferase 1A6. Biochemistry 41:12813-12820.
13. Itäaho K, Court MH, Uutela P, Kostiainen R, Radominska-Pandya A, and Finel M (2009) Dopamine is a low-affinity and high-specificity substrate for the human UDPglucuronosyltransferase 1A10. Drug Metab Dispos 37:768-775.
14. Itäaho K, Mackenzie PI, Ikushiro S, Miners JO, and Finel M (2008) The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP- glucuronosyltransferases. Drug Metab Dispos 36:2307-2315.
15. Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, Aoki Y, Ikushiro S, Sakaki T, and Yokoi T (2009) Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos 37:1759-1768.
16. Kaivosaari S, Toivonen P, Aitio O, Sipilä J, Koskinen M, Salonen JS, and Finel M (2008) Regioand stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes. Drug Metab Dispos 36:1529-1537.
17. Kamata T, Katagi M, Kamata HT, Miki A, Shima N, Zaitsu K, Nishikawa M, Tanaka E, Honda K, and Tsuchihashi H (2006) Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: identification and quantification of its urinary metabolites. Drug Metab Dispos 34:281-287.
18. Kamata T, Nishikawa M, Katagi M, and Tsuchihashi H (2006) Direct detection of serum psilocin glucuronide by LC/MS and LC/MS/MS: time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a "magic mushroom" user. Forensic Toxicol 24:36-40.
19. Kamata T, Nishikawa M, Katagi M, and Tsuchihashi H (2003) Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 796:421-427.
20. King CD, Rios GR, Green MD, and Tephly TR (2000) UDP- glucuronosyltransferases. Curr Drug Metab 1:143-161.
21. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
22. Krishnaswamy S, Duan SX, Von Moltke LL, Greenblatt DJ, and Court MH (2003) Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Dispos 31:133-139.
23. Krishnaswamy S, Hao Q, Von Moltke LL, Greenblatt DJ, and Court MH (2004) Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6. Drug Metab Dispos 32:862-869.
24. Kurkela M, Patana AS, Mackenzie PI, Court MH, Tate CG, Hirvonen J, Goldman A, and Finel M (2007) Interactions with other human UDP- glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. Pharmacogenet Genomics 17:115-126.
25. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
26. Migliaccio GP, Shieh TL, Byrn SR, Hathaway BA, and Nichols DE (1981) Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. J Med Chem 24:206-209.
27. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, and Yokoi T (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
28. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
29. Shirota O, Hakamata W, and Goda Y (2003) Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of "magic mushroom." J Nat Prod 66:885-887.
30. Sneitz N, Court MH, Zhang X, Laajanen K, Yee KK, Dalton P, Ding X, and Finel M (2009) Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A. Pharmacogenet Genomics.
31. Stamets P (2003) Psilocybin Mushrooms of the World: An Identification Guide, 1st edition ed. Ten Speed Press.
32. Sticht G and Käferstein H (2000) Detection of psilocin in body fluids. Forensic Sci Int 113:403-407.
33. Tsujikawa K, Kanamori T, Iwata Y, Ohmae Y, Sugita R, Inoue H, and Kishi T (2003) Morphological and chemical analysis of magic mushrooms in Japan. Forensic Sci Int 138: 85-90.
34. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
35. Turgeon D, Carrier JS, Lévesque E, Hum DW, and Bélanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787.